{"schema_version":"1","generated_at":"2026-10-31T10:59:05.388Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mark-frattini","json_url":"https://www.findmykol.com/kol/mark-frattini/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mark-frattini","name":"Mark Frattini","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Roswell Park Comprehensive Cancer Center","institution_url":"https://www.findmykol.com/institution/roswell-park-comprehensive-cancer-center","city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1881665669","openalex":"A5110103402"},"summary":"Mark Frattini is an Oncology physician affiliated with Roswell Park Comprehensive Cancer Center. OpenAlex indexes 153 publications with 11,449 citations (h-index 36).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":153,"cited_by_count":11449,"h_index":36,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":4,"shown":3,"withheld":1,"rows":[{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":84.65,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881665669"},{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":60,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881665669"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":46.52,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881665669"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1881665669","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":2026,"last":2026},"rows_total":2,"shown":2,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"P30CA016056","title":"Clinical Protocol and Data Management","fiscal_year":2026,"amount_usd":"544393","organization":"ROSWELL PARK CANCER INSTITUTE CORP","source_url":"https://reporter.nih.gov/quickSearch/P30CA016056"},{"project":"P30CA016056","title":"Protocol Review and Monitoring System","fiscal_year":2026,"amount_usd":"180088","organization":"ROSWELL PARK CANCER INSTITUTE CORP","source_url":"https://reporter.nih.gov/quickSearch/P30CA016056"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)","year":2023,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2023-187252","status":"verified"},{"title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)","year":2022,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2022-169928","status":"verified"},{"title":"A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome","year":2022,"journal":"Journal of Cancer Research and Clinical Oncology","source_url":"https://doi.org/10.1007/s00432-022-03983-6","status":"verified"},{"title":"CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights","year":2022,"journal":"Leukemia Research","source_url":"https://doi.org/10.1016/j.leukres.2022.106928","status":"verified"},{"title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(21)00494-0","status":"verified"}],"source":"works"},"contact":{"address_1":"1275 YORK AVE","city":"New York","state":"NY","zip":"100216007","phone":"646-227-3813","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1881665669","source":"identity"},"similar":[{"name":"Igor Puzanov","slug":"igor-puzanov","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/igor-puzanov","json_url":"https://www.findmykol.com/kol/igor-puzanov/profile.json"},{"name":"Philip McCarthy","slug":"philip-mccarthy","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/philip-mccarthy","json_url":"https://www.findmykol.com/kol/philip-mccarthy/profile.json"},{"name":"Saby George","slug":"saby-george","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/saby-george","json_url":"https://www.findmykol.com/kol/saby-george/profile.json"},{"name":"Eunice Wang","slug":"eunice-wang","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/eunice-wang","json_url":"https://www.findmykol.com/kol/eunice-wang/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":1,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2016-06-13","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}